[2021] MEA Technetium-99m Market Size, Development Status, Future Demands, Emerging Trends, Growing At A CAGR of 8.3% | Coherent Market Insights

SEATTLE, May 04, 2021, (PHARMIWEB) —

Overview:

As a radioactive tracer, technetium-99m is used in nuclear medicine medical imaging procedures. It has a six-hour half-life and does not last long in the body or in the atmosphere. Tc-99m is primarily used in bone and brain scans using single photon emission computed tomography (SPECT).

The MEA technetium-99m market is expected to reach US$ 688.5 million by the end of 2027, increasing from US$ 394.6 million in 2019

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/3874

Drivers:

Over the projected era, the demand for MEA technetium-99m is expected to rise due to the increasing use of radio isotopes in drug distribution. Innovation Pharma announced in February 2020 that the Phase 1 trial evaluating the use of delayed-release Brilacidin tablets met its primary endpoints. Brilacidin was radiolabeled with complexed technetium-99m in the study’s timed-release OralogiK formulation.

Opportunities:

For players in the MEA technetium-99m industry, R&D is expected to provide attractive growth opportunities. Researchers from South Korea’s Seoul National University College of Medicine documented the production of 99mTc-tricabonyl labelled urea-based prostate-specific membrane antigen conjugates with isonitrile-coordinating ligands in January 2020.

Restraints:

Radiation sensitivity to technicians, staff, and passers-by is increased when Tc-99m is used in diagnostic imaging. In comparison, infants and young adults are at a larger risk. The market’s growth is likely to be hampered by such side effects.

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/3874

Market Trends:

Hyperlipidemia-related disorders may also be associated with technetium-99m. Researchers from Kyoto University in Japan announced in June 2019 that [99mTc] Tc- boron dipyrromethene could be used as an imaging probe for detecting lipid droplets in hyperlipidemia disease lesions.

The industry’s major players are concentrating on implementing different marketing campaigns in order to increase their market share. At the Society of Nuclear Medicine and Molecular Imaging Annual Meeting in June 2019, NorthStar Medical Radioisotopes, LLC discussed domestic Mo-99 manufacturing, expansion plans, and the use of the RadioGenix System (technetium 99m generator).

Competitive Landscape:

Key companies contributing in MEA technetium-99m market are Sumitomo Corporation, GE Healthcare, NorthStar Medical Radioisotopes, Siemens Healthineers, IBA, and Advanced Cyclotron Systems, Inc.

Key Developments:

IBA Industrial, a division of Ion Beam Applications S.A., announced that NorthStar Medical Radioisotopes has placed an order for two Rhodotron TT300 HE electron beam accelerators.

Advanced Cyclotron Systems, Inc. attended the Society of Nuclear Medicine and Molecular Imaging’s Annual Meeting in Pennsylvania, U.S., in June 2018.

Buy This Complete A Business Report: https://www.coherentmarketinsights.com/insight/buy-now/3874

Detailed Segmentation

• MEA Technetium-99m Market, By Isotopic Application:
  • Gamma Camera
  • SPECT
• MEA Technetium-99m Market, By End User:
  • Hospitals
  • Diagnostic Center

View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/mea-technetium-99m-market-3142

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contacts US:

Mr. Shah
Coherent Market Insights,
1001 4th Ave,
#3200 Seattle, WA 98154, U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
Email: sales@coherentmarketinsights.com